Shenzhen China Resources Gosun Pharmaceuticals, Co., Ltd. is a prominent pharmaceutical company established in 1992, specialising in the development, manufacturing, and marketing of Cephalosporin products in China. With an annual production capacity of 200 million vials of formulation, the company has positioned itself as a leader in the industry. Notably, it was the first pharmaceutical company in China to achieve EU GMP certification for both sterile API and formulation workshops. Since 2011, Shenzhen China Resources Gosun Pharmaceuticals has expanded its market reach by exporting finished products to Europe, while also establishing a long-standing presence in Africa for over a decade. The company collaborates with multinational corporations, enhancing its portfolio and reputation in the global pharmaceutical landscape.

Key products and services

• Production of sterile cephalosporin powders and sterile cephalosporin injection formulations: for example, Cefazolin Sodium Pentahydrate for Injection, Cefuroxime Sodium for Injection, Cefonicid Sodium, Cefotaxime Sodium, Ceftezole Sodium, etc.
• Manufacturing of APIs and intermediates to meet international quality standards (EP, USP, BP).
• Development, manufacturing and commercialisation of oral preparations and injectables, particularly in anti-infectives and peri-operative care.
• CDMO / CMO type partnering for other pharmaceutical companies: including licensing, development, manufacturing and commercialisation rights in various territories.

CR Gosun has distinguished itself in China’s pharmaceutical sector through its longstanding expertise in anti-infectives, sterile APIs and injectable formulations, coupled with robust quality certifications such as EU-GMP. Its commitment to peri-operative care and the development of clinically important products, alongside strategic international partnerships, underscores CR Gosun’s ambition to operate at both domestic and global levels. With its integrated capabilities in R&D, manufacturing and marketing, the company is well positioned to address evolving demands in anti-infective therapy and surgical prophylaxis.